PHR250117P35000
- 0.00
- 0.000.00%
Phreesia Newsroom
Phreesia Price Target Raised to $35.00/Share From $31.00 by Citigroup
Phreesia Analyst Ratings
Needham Maintains Phreesia(PHR.US) With Buy Rating, Maintains Target Price $29
Citi Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $35
Phreesia's Growth Potential and Balanced Strategy Justifies Buy Rating
Phreesia Is Maintained at Overweight by Keybanc
Phreesia Analyst Ratings
KeyBanc Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $30
RBC Capital Upgrades Phreesia(PHR.US) to Buy Rating, Raises Target Price to $32
RBC Upgrades Phreesia to Outperform From Sector Perform, Raises Price Target to $32 From $24
D.A. Davidson Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $36
Phreesia (PHR) Receives a Buy From J.P. Morgan
RBC Capital Sticks to Its Hold Rating for Phreesia (PHR)
Analysts Offer Insights on Healthcare Companies: Pharming Group (OtherPHGUF) and Phreesia (PHR)
Truist Financial Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $34
Phreesia Is Maintained at Buy by Truist Securities
Truist Financial Initiates Phreesia(PHR.US) With Buy Rating, Announces Target Price $34
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $28 to $30
Truist Raises Price Target on Phreesia to $34 From $31, Keeps Buy Rating
Baird Maintains Outperform on Phreesia, Lowers Price Target to $30